Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo
- PMID: 8058316
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo
Abstract
H4(D10S170) is a gene which we isolated because of its frequent rearrangement with the RET proto-oncogene in vivo. Its fusion to RET generates the RET/PTC1 oncogene, which has been detected in about 20% of human thyroid papillary carcinomas. We have cloned and sequenced the cDNA corresponding to the H4(D10S170) gene from a human normal thyroid cDNA library. The nucleotide sequence of the H4(D10S170) 3 kb transcript shows no significant homology to known genes and contains an open reading frame (ORF) of 585 amino acids. H4(D10S170) predicted protein has no transmembrane domain and shows extensive regions in the alpha helical conformation, which are 30% homologous to the alpha-helical domains of several proteins including tropomyosin, vimentin, keratin and the tail region of myosin heavy chain. A putative SH3 binding site is present at the carboxy terminus, which suggests that H4(D10S170) might be a cytoskeletal protein.
Similar articles
-
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.Oncogene. 2004 Jan 8;23(1):109-21. doi: 10.1038/sj.onc.1206981. Oncogene. 2004. PMID: 14712216
-
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene. 1994 Feb;9(2):509-16. Oncogene. 1994. PMID: 8290261
-
Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene.Oncogene. 1995 May 4;10(9):1781-7. Oncogene. 1995. PMID: 7753554
-
Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl.Thyroid. 1998 Nov;8(11):1003-8. doi: 10.1089/thy.1998.8.1003. Thyroid. 1998. PMID: 9848713 Review.
-
The ret/PTC oncogene in papillary thyroid carcinoma.J Lab Clin Med. 1994 Mar;123(3):331-7. J Lab Clin Med. 1994. PMID: 8133143 Review. No abstract available.
Cited by
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Depletion of CDC5L inhibits bladder cancer tumorigenesis.J Cancer. 2020 Jan 1;11(2):353-363. doi: 10.7150/jca.32850. eCollection 2020. J Cancer. 2020. PMID: 31897231 Free PMC article.
-
Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.Oncotarget. 2015 Jun 20;6(17):15628-38. doi: 10.18632/oncotarget.3858. Oncotarget. 2015. PMID: 25970781 Free PMC article.
-
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer Sci. 2013 Jul;104(7):896-903. doi: 10.1111/cas.12175. Epub 2013 May 12. Cancer Sci. 2013. PMID: 23578175 Free PMC article.
-
Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.PLoS One. 2012;7(11):e49298. doi: 10.1371/journal.pone.0049298. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23145146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases